JP2025517356A5 - - Google Patents
Info
- Publication number
- JP2025517356A5 JP2025517356A5 JP2024568250A JP2024568250A JP2025517356A5 JP 2025517356 A5 JP2025517356 A5 JP 2025517356A5 JP 2024568250 A JP2024568250 A JP 2024568250A JP 2024568250 A JP2024568250 A JP 2024568250A JP 2025517356 A5 JP2025517356 A5 JP 2025517356A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- individual
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263343506P | 2022-05-18 | 2022-05-18 | |
| US63/343,506 | 2022-05-18 | ||
| PCT/US2023/067146 WO2023225577A1 (en) | 2022-05-18 | 2023-05-17 | Methods of treating cancer using anti-cd22 antibody oligonucleotide conjugates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025517356A JP2025517356A (ja) | 2025-06-05 |
| JP2025517356A5 true JP2025517356A5 (enExample) | 2026-05-18 |
Family
ID=88836107
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024568250A Pending JP2025517356A (ja) | 2022-05-18 | 2023-05-17 | 抗ｃｄ２２抗体オリゴヌクレオチドコンジュゲートを使用したがんの治療方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20260115309A1 (enExample) |
| EP (1) | EP4525930A1 (enExample) |
| JP (1) | JP2025517356A (enExample) |
| KR (1) | KR20250039518A (enExample) |
| CN (1) | CN119546345A (enExample) |
| WO (1) | WO2023225577A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4791443A1 (en) * | 2023-10-13 | 2026-08-19 | Tallac Therapeutics, Inc. | Methods of treating cancer using anti-cd22 antibody oligonucleotide conjugates |
| CN120324454A (zh) * | 2024-01-17 | 2025-07-18 | 安升（上海）医药科技有限公司 | 多肽-寡核苷酸复合物及其用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019360216A1 (en) * | 2018-10-17 | 2021-05-13 | Tallac Therapeutics, Inc. | Immunomodulating polynucleotide conjugates and methods of use |
| IL295759A (en) * | 2020-02-28 | 2022-10-01 | Tallac Therapeutics Inc | Transglutaminase mediated coupling |
| US20230364255A1 (en) * | 2020-08-18 | 2023-11-16 | Tallac Therapeutics, Inc. | Transglutaminase-mediated conjugation |
| TW202328185A (zh) * | 2021-08-25 | 2023-07-16 | 美商泰勒克療法公司 | SIRP-α抗體及結合物 |
-
2023
- 2023-05-17 KR KR1020247042026A patent/KR20250039518A/ko active Pending
- 2023-05-17 WO PCT/US2023/067146 patent/WO2023225577A1/en not_active Ceased
- 2023-05-17 CN CN202380051762.1A patent/CN119546345A/zh active Pending
- 2023-05-17 JP JP2024568250A patent/JP2025517356A/ja active Pending
- 2023-05-17 EP EP23808558.3A patent/EP4525930A1/en active Pending
-
2024
- 2024-11-14 US US18/948,373 patent/US20260115309A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023539715A5 (enExample) | ||
| JP2021058197A5 (enExample) | ||
| JP2022095908A5 (enExample) | ||
| JP2021513541A5 (enExample) | ||
| JP2018537975A5 (enExample) | ||
| JPWO2020122034A5 (enExample) | ||
| JP2020515578A5 (enExample) | ||
| TW202019487A (zh) | 抗體-藥物結合物及微管蛋白抑制劑之組合 | |
| CN111132696B (zh) | Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途 | |
| JP2010535713A5 (enExample) | ||
| TW201922793A (zh) | Ｐｄ－１抗體和ｖｅｇｆｒ抑制劑聯合治療小細胞肺癌的用途 | |
| JP2023545096A5 (enExample) | ||
| JP2021515017A5 (enExample) | ||
| JP2020500834A5 (enExample) | ||
| JP2019524713A5 (enExample) | ||
| JP2021511372A5 (enExample) | ||
| JP2018512402A5 (enExample) | ||
| TW202330040A (zh) | 抗ｈｅｒ２抗體藥物偶聯物和酪胺酸激酶抑制劑聯合在製備治療腫瘤的藥物中的用途 | |
| JP2022541591A5 (enExample) | ||
| JPWO2022270524A5 (enExample) | ||
| JP2025509266A5 (enExample) | ||
| EP4464337A1 (en) | Combined use of anti-trop-2 antibody-drug conjugate and other therapeutic agents | |
| CN118201963A (zh) | 用于治疗非小细胞肺癌的药物组合 | |
| CN116712539A (zh) | 抗her2抗体药物偶联物和抗pd-1抗体联合在制备治疗肿瘤的药物中的用途 | |
| JP2023514167A5 (enExample) |